Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, induces dilation of isolated porcine retinal arterioles: Role of nitric oxide and potassium channels

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 9, 2011, Pages 6749-6756

  Omae, Tsuneaki ^a   Nagaoka, Taiji ^a   Tanano, Ichiro ^a   Yoshida, Akitoshi ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1H 1, 2, 4 OXADIAZOLO [4, 3 A] QUINOXALIN 1 ONE; 2 CHLORO 5 NITROBENZANILIDE; 4 AMINOPYRIDINE; ALPHA SMOOTH MUSCLE ACTIN; CYTOCHROME P450; GUANYLATE CYCLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; N (G) NITROARGININE METHYL ESTER; NITRATE; NITRIC OXIDE SYNTHASE; NITRITE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; PROTEIN KINASE B; TETRYLAMMONIUM; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; WORTMANNIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POTASSIUM CHANNEL;

ANIMAL TISSUE; ARTERIOLE; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RETINA BLOOD VESSEL; SWINE; ANIMAL; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; IN VITRO STUDY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA ARTERY; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; ARTERIOLES; CALCIUM CHANNEL BLOCKERS; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; HYPOGLYCEMIC AGENTS; MALE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; POTASSIUM CHANNELS; PPAR GAMMA; RETINAL ARTERY; SUS SCROFA; THIAZOLIDINEDIONES; VASODILATION;

EID: 80054789683     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6826     Document Type: Article

References (46)

1. Porte D Jr, Schwartz MW. Diabetes complications: why is glucose potentially toxic? Science. 1996;272:699-700.
2. Konno S, Feke GT, Yoshida A, Fujio N, Goger DG, Buzney SM. Retinal blood flow changes in type I diabetes: a long-term follow-up study. Invest Ophthalmol Vis Sci. 1996;37:1140-1148.
3. Bursell SE, Clermont AC, Kinsley BT, Simonson DC, Aiello LM, Wolpert HA. Retinal blood flow changes in patients with insulindependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci. 1996;37:886-897.
4. Grunwald JE, Riva CE, Sinclair SH, Brucker AJ, Petrig BL. Laser Doppler velocimetry study of retinal circulation in diabetes mellitus. Arch Ophthalmol. 1986;104:991-996.
5. Nagaoka T, Sato E, Takahashi A, Yokota H, Sogawa K, Yoshida A. Impaired retinal circulation in patients with type 2 diabetes mellitus: retinal laser Doppler velocimetry study. Invest Ophthalmol Vis Sci. 2010;51:6729-6734.
6. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-1118.
7. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
8. Calkin AC, Forbes JM, Smith CM, et al. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol. 2005;25: 1903-1909.
9. Ji S, Kronenberg G, Balkaya M, et al. Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome. Exp Neurol. 2009;216:321-328.
10. Ren Y, Sun C, Sun Y, et al. PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation. Vascul Pharmacol. 2009;51:169-174.
11. Shen LQ, Child A, Weber GM, Folkman J, Aiello LP. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol. 2008;126:793-799.
12. Murata T, He S, Hangai M, et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:2309-2317.
13. Higuchi A, Ohashi K, Shibata R, Sono-Romanelli S, Walsh K, Ouchi N. Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism. Arterioscler Thromb Vasc Biol. 2010;30:46-53.
14. Hein TW, Yuan Z, Rosa RH Jr, Kuo L. Requisite roles of A2A receptors, nitric oxide, and KATP channels in retinal arteriolar dilation in response to adenosine. Invest Ophthalmol Vis Sci. 2005;46:2113-2119.
15. Hein TW, Xu W, Kuo L. Dilation of retinal arterioles in response to lactate: role of nitric oxide, guanylyl cyclase, and ATP-sensitive potassium channels. Invest Ophthalmol Vis Sci. 2006;47:693-699.
16. Nagaoka T, Hein TW, Yoshida A, Kuo L. Simvastatin elicits dilation of isolated porcine retinal arterioles: role of nitric oxide and mevalonate-rho kinase pathways. Invest Ophthalmol Vis Sci. 2007; 48:825-832.
17. Glucksberg MR, Dunn R. Direct measurement of retinal microvascular pressures in the live, anesthetized cat. Microvasc Res. 1993; 45:158-165.
18. Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs. 2006;66:85-109.
19. Hein TW, Kuo L. cAMP-independent dilation of coronary arterioles to adenosine: role of nitric oxide, G proteins, and K(ATP) channels. Circ Res. 1999;85:634-642.
20. Earley S, Pastuszyn A, Walker BR. Cytochrome p-450 epoxygenase products contribute to attenuated vasoconstriction after chronic hypoxia. Am J Physiol Heart Circ Physiol. 2003;285:H127-H136.
21. Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J. 1993;296:297-301.
22. Thors B, Halldorsson H, Jonsdottir G, Thorgeirsson G. Mechanism of thrombin mediated eNOS phosphorylation in endothelial cells is dependent on ATP levels after stimulation. Biochim Biophys Acta. 2008;1783:1893-1902.
23. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferatoractivated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem. 1999;274:9116-9121.
24. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998;83:1097-1103.
25. Seargent JM, Yates EA, Gill JH. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol. 2004; 143:933-937.
26. Boyle JG, Logan PJ, Ewart MA, et al. Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase. J Biol Chem. 2008;283:11210-11217.
27. Dalsgaard T, Kroigaard C, Bek T, Simonsen U. Role of calciumactivated potassium channels with small conductance in bradykinin-induced vasodilation of porcine retinal arterioles. Invest Ophthalmol Vis Sci. 2009;50:3819-3825.
28. Nagaoka T, Hein TW, Yoshida A, Kuo L. Resveratrol, a component of red wine, elicits dilation of isolated porcine retinal arterioles: role of nitric oxide and potassium channels. Invest Ophthalmol Vis Sci. 2007;48:4232-4239.
29. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol. 1995; 268:C799-C822.
30. Hein TW, Liao JC, Kuo L. oxLDL specifically impairs endotheliumdependent, NO-mediated dilation of coronary arterioles. Am J Physiol Heart Circ Physiol. 2000;278:H175-H183.
31. Gauthier KM, Spitzbarth N, Edwards EM, Campbell WB. Apaminsensitive K+ currents mediate arachidonic acid-induced relaxations of rabbit aorta. Hypertension. 2004;43:413-419.
32. Overturf KE, Russell SN, Carl A, et al. Cloning and characterization of a Kv1.5 delayed rectifier K+ channel from vascular and visceral smooth muscles. Am J Physiol. 1994;267:C1231-C1238.
33. Rivers RJ, Hein TW, Zhang C, Kuo L. Activation of barium-sensitive inward rectifier potassium channels mediates remote dilation of coronary arterioles. Circulation. 2001;104:1749-1753.
34. Tsikas D. Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the L-arginine/nitric oxide area of research. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:51-70.
35. Nomura H, Yamawaki H, Mukohda M, Okada M, Hara Y. Mechanisms underlying pioglitazone-mediated relaxation in isolated blood vessel. J Pharmacol Sci. 2008;108:258-265.
36. Majithiya JB, Paramar AN, Balaraman R. Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res. 2005;66:150-161.
37. Heppner TJ, Bonev AD, Eckman DM, Gomez MF, Petkov GV, Nelson MT. Novel PPARgamma agonists GI 262570, GW7845, GW1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries. Pharmacology. 2005;73:15-22.
38. Seto SW, Lam TY, Leung GP, et al. Comparison of vascular relaxation, lipolysis and glucose uptake by peroxisome proliferatoractivated receptor-gamma activation in +db/+m and +db/+db mice. Eur J Pharmacol. 2007;572:40-48.
39. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension. 1994;24:170-175.
40. Stankevicius E, Kevelaitis E, Vainorius E, Simonsen U. Role of nitric oxide and other endothelium-derived factors (in Lithuanian). Medicina (Kaunas). 2003;39:333-341.
41. Wynne AM, Mocanu MM, Yellon DM. Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK. J Cardiovasc Pharmacol. 2005;46:817-822.
42. Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006;55:496-505.
43. Rubin LJ, Magliola L, Feng X, Jones AW, Hale CC. Metabolic activation of AMP kinase in vascular smooth muscle. J Appl Physiol. 2005;98:296-306.
44. Levine YC, Li GK, Michel T. Agonist-modulated regulation of AMPactivated protein kinase (AMPK) in endothelial cells. Evidence for an AMPK3Rac13Akt3endothelial nitric-oxide synthase pathway. J Biol Chem. 2007;282:20351-20364.
45. Zou MH, Kirkpatrick SS, Davis BJ, et al. Activation of the AMPactivated protein kinase by the anti-diabetic drug metformin in vivo: role of mitochondrial reactive nitrogen species. J Biol Chem. 2004;279:43940-43951.
46. Nakamura Y, Ohya Y, Onaka U, Fujii K, Abe I, Fujishima M. Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br J Pharmacol. 1998;123:675-682.